Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.95
−$0.34 · -1.40%
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Latest quote
$23.95
−$0.34 · -1.40%
After-hours
$23.95
$0.00 · 0.00%
Oct 8, 5:46 PM ET
Regular session · ET · Market data may be delayed.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Day range
Current $23.95
52-week range
Current $23.95
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
52
Fair Value
Sentiment
34
Bearish
Risk
43
Elevated Risk
Momentum
46
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Day range
Current $23.95
52-week range
Current $23.95
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 184.42M USD | 36.56M USD | 8.78M USD | 12.41M USD | — |
| Gross profit | 184.42M USD | 36.56M USD | 8.78M USD | 12.41M USD | — |
| Research and development | 137.92M USD | 89.13M USD | 82.23M USD | 77.84M USD | 54.17M USD |
| Selling, general, and administrative | 67.09M USD | 48.79M USD | 41.32M USD | 38.92M USD | 31.9M USD |
| Operating expenses | 205.01M USD | 137.93M USD | 123.55M USD | 116.76M USD | 86.07M USD |
| Interest income | 13.77M USD | 12.64M USD | 9.91M USD | 3.12M USD | 120K USD |
| Interest expense | 9K USD | — | — | — | — |
| Depreciation and amortization | 1.77M USD | 2.18M USD | 2.47M USD | 1.55M USD | 974K USD |
| Operating income | −20.59M USD | −101.37M USD | −114.77M USD | −104.36M USD | −86.07M USD |
| Net income | −6.89M USD | −88.98M USD | −104.7M USD | −101.07M USD | −85.81M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI59.01M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM35.14M0.04%78.56B USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI32.74M0.32%10.08B USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF20.29M0.02%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO12.52M0.09%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO9.88M0.05%18B USD0.06%$112.1-0.10%
iShares Biotechnology ETFIBB9.83M0.09%10.4B USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS8.52M0.03%33.66B USD0.31%$78.10+0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.